Inlyta FDA Approval History
FDA Approved: Yes (First approved January 27, 2012)
Brand name: Inlyta
Generic name: axitinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Renal Cell Carcinoma
Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
Development Timeline for Inlyta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.